Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Mirabegron-solifenacin combo safe, effective for overactive bladder

21 Nov 2019

Mirabegron in combination with solifenacin is effective against overactive bladder (OAB) and comes with a good tolerability profile, a recent study has shown.

Researchers conducted a literature search of the databases of Embase, Cochrane and Medline for studies reporting on the efficacy and safety of antimuscarinic agents either in combination with each other or with a β3-adrenoreceptor agonists for OAB. Twenty-one publications, one of which was a conference abstract, were deemed eligible for inclusion.

One phase II trial was included, which employed a double-blind, placebo- and monotherapy-controlled, dose-ranging design. Compared with 5-mg solifenacin monotreatment, all combinations of 5- and 10-mg solifenacin with any dose of mirabegron resulted in significantly better mean volume voided per micturition.

Three combinations―10-mg solifenacin and 25-mg mirabegron, 5-mg solifenacin and 50-mg mirabegron, and 10-mg solifenacin and 50-mg mirabegron―significantly reduced micturition frequency from baseline. Aside from a slightly elevated frequency of constipation in patients treated with combination medication, no significant treatment-emergent adverse events were reported.

Three phase III/IIIb trials of mirabegron with solifenacin were included. Taken together, these studies showed that in treatment-naïve patients, the combination of solifenacin with mirabegron successfully reduced urinary incontinence episodes and micturitions relative to corresponding monotherapy doses.

The combination was also effective in those with initially inadequate responses to solifenacin alone and received mirabegron as an add-on.

These improvements in medication efficacy did not come with significant tradeoff, as no adverse event occurred with a significantly greater frequency in those receiving combination intervention.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.